Bile Acid Metabolism and Signaling

被引:1095
作者
Chiang, John Y. L. [1 ]
机构
[1] Northeast Ohio Med Univ, Rootstown, OH USA
关键词
FARNESOID-X-RECEPTOR; CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; SALT EXPORT PUMP; ALPHA-OST-BETA; FATTY LIVER-DISEASE; DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY; NEGATIVE FEEDBACK-REGULATION; FIBROBLAST GROWTH FACTOR-19; ORGANIC SOLUTE TRANSPORTER; TYPE-2; DIABETES-MELLITUS;
D O I
10.1002/cphy.c120023
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Bile acids are important physiological agents for intestinal nutrient absorption and biliary secretion of lipids, toxic metabolites, and xenobiotics. Bile acids also are signaling molecules and metabolic regulators that activate nuclear receptors and G protein-coupled receptor (GPCR) signaling to regulate hepatic lipid, glucose, and energy homeostasis and maintain metabolic homeostasis. Conversion of cholesterol to bile acids is critical for maintaining cholesterol homeostasis and preventing accumulation of cholesterol, triglycerides, and toxic metabolites, and injury in the liver and other organs. Enterohepatic circulation of bile acids from the liver to intestine and back to the liver plays a central role in nutrient absorption and distribution, and metabolic regulation and homeostasis. This physiological process is regulated by a complex membrane transport system in the liver and intestine regulated by nuclear receptors. Toxic bile acids may cause inflammation, apoptosis, and cell death. On the other hand, bile acid-activated nuclear and GPCR signaling protects against inflammation in liver, intestine, and macrophages. Disorders in bile acid metabolism cause cholestatic liver diseases, dyslipidemia, fatty liver diseases, cardiovascular diseases, and diabetes. Bile acids, bile acid derivatives, and bile acid sequestrants are therapeutic agents for treating chronic liver diseases, obesity, and diabetes in humans. (C) 2013 American Physiological Society.
引用
收藏
页码:1191 / 1212
页数:22
相关论文
共 224 条
  • [1] Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
    Adorini, Luciano
    Pruzanski, Mark
    Shapiro, David
    [J]. DRUG DISCOVERY TODAY, 2012, 17 (17-18) : 988 - 997
  • [2] Agellon LB, 1997, BIOCHEM J, V328, P393
  • [3] Colesevelam hydrochloride: A novel bile acid-binding resin
    Aldridge, MA
    Ito, MK
    [J]. ANNALS OF PHARMACOTHERAPY, 2001, 35 (7-8) : 898 - 907
  • [4] Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1
    Alvarez, L
    Jara, P
    Sánchez-Sabaté, E
    Hierro, L
    Larrauri, J
    Díaz, MC
    Camarena, C
    De la Vega, A
    Frauca, E
    López-Collazo, E
    Lapunzina, P
    [J]. HUMAN MOLECULAR GENETICS, 2004, 13 (20) : 2451 - 2460
  • [5] Bile acids: regulation of apoptosis by ursodeoxycholic acid
    Amaral, Joana D.
    Viana, Ricardo J. S.
    Ramalho, Rita M.
    Steer, Clifford J.
    Rodrigues, Cecilia M. P.
    [J]. JOURNAL OF LIPID RESEARCH, 2009, 50 (09) : 1721 - 1734
  • [6] ANGELIN B, 1978, J LIPID RES, V19, P1004
  • [7] ANGELIN B, 1978, J LIPID RES, V19, P1017
  • [8] One or more labile proteins regulate the stability of chimeric mRNA containing the 3′-untranslated region of cholesterol-7α-hydroxylase mRNA
    Baker, DM
    Wang, SL
    Bell, DJ
    Drevon, CA
    Davis, RA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (26) : 19985 - 19991
  • [9] OSTα-OSTβ:: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia
    Ballatori, N
    Christian, WV
    Lee, JY
    Dawson, PA
    Soroka, CJ
    Boyer, JL
    Madejczyk, MS
    Li, N
    [J]. HEPATOLOGY, 2005, 42 (06) : 1270 - 1279
  • [10] Ostα-Ostβ is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver
    Ballatori, Nazzareno
    Fang, Fang
    Christian, Whitney V.
    Li, Na
    Hammond, Christine L.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2008, 295 (01): : G179 - G186